← Back to Screener
Greenwich LifeSciences, Inc. (GLSI)
Price$27.10
Favorite Metrics
Price vs S&P 500 (26W)122.40%
Price vs S&P 500 (4W)-8.82%
Market Capitalization$358.97M
All Metrics
Book Value / Share (Quarterly)$0.16
P/TBV (Annual)58.29x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.62
Price vs S&P 500 (YTD)20.68%
EPS (TTM)$-1.46
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-1.46
EPS (Annual)$-1.21
ROI (Annual)-623.07%
Cash / Share (Quarterly)$0.28
ROA (Last FY)-385.68%
EBITD / Share (TTM)$-1.47
ROE (5Y Avg)-167.76%
Cash Flow / Share (Annual)$-0.55
P/B Ratio164.29x
P/B Ratio (Quarterly)62.07x
Net Income / Employee (Annual)$-4
ROA (TTM)-565.47%
EPS Incl Extra (Annual)$-1.21
Current Ratio (Annual)2.62x
Quick Ratio (Quarterly)2.35x
3-Month Avg Trading Volume0.43M
52-Week Price Return179.20%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.16
52-Week High$34.10
EPS Excl Extra (Annual)$-1.21
26-Week Price Return126.39%
Quick Ratio (Annual)2.62x
13-Week Price Return-3.43%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.35x
Enterprise Value$355.164
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.31
3-Month Return Std Dev112.70%
Net Income / Employee (TTM)$-5
ROE (Last FY)-623.07%
EPS Basic Excl Extra (Annual)$-1.21
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.46
ROI (TTM)-1042.76%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.19
Price vs S&P 500 (52W)149.37%
Year-to-Date Return23.32%
5-Day Price Return0.35%
EPS Normalized (Annual)$-1.21
ROA (5Y Avg)-118.83%
Month-to-Date Return7.87%
Cash Flow / Share (TTM)$-0.48
EBITD / Share (Annual)$-1.23
ROI (5Y Avg)-167.75%
EPS Basic Excl Extra (TTM)$-1.46
P/TBV (Quarterly)62.07x
P/B Ratio (Annual)58.25x
Book Value / Share (Annual)$0.19
Price vs S&P 500 (13W)-4.12%
Beta1.49x
Revenue / Share (TTM)$0.00
ROE (TTM)-1042.76%
52-Week Low$7.78
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GLSIGreenwich LifeSciences, Inc. | — | — | — | — | $27.10 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy combining GP2 and GM-CSF to prevent breast cancer recurrence in patients with HER2/neu-expressing tumors, which represent approximately 75% of breast cancers. The company is advancing GLSI-100 through its Phase III Flamingo-01 trial and expanding operations into Europe with plans to establish up to 150 clinical trial sites globally.